Constructed Tumor-Targeted and MMP-2 Biocleavable Antibody Conjugated Silica Nanoparticles for Efficient Cancer Therapy

Hao Wu; Xuefeng Ding; Yun Chen; Yanfei Cai; Zhaoqi Yang; Jian Jin

doi:10.1021/acsomega.2c07949

Constructed Tumor-Targeted and MMP-2 Biocleavable Antibody Conjugated Silica Nanoparticles for Efficient Cancer Therapy

ACS Omega. 2023 Mar 29;8(14):12752-12760. doi: 10.1021/acsomega.2c07949. eCollection 2023 Apr 11.

Authors

Hao Wu¹, Xuefeng Ding², Yun Chen¹, Yanfei Cai¹, Zhaoqi Yang¹, Jian Jin¹

Affiliations

¹ School of Life Sciences and Health Engineering, Jiangnan University, 1800 Lihu Avenue, Wuxi 214000, People's Republic of China.
² School of Biotechnology, Jiangnan University, 1800 Lihu Avenue, Wuxi 214000, People's Republic of China.

Abstract

Antibody-drug conjugates (ADC) are an inevitable trend in the development of modern "precision medicine". The goal of this work is to produce enzyme-responsive antibody nanoparticle-loaded medication (FMSN-Dox-H2-AE01) based on the EGFR antibody (AE01) and human serum albumin (HSA) shelled mesoporous silica nanoparticles. HSA and antibodies on the surface of the particlescan not only enhance the biocompatibility of the particle and avoid early drug leakage but also allow selective biodegradation triggered by matrix metalloproteinase-2 (MMP-2), which are overexpressed enzymes in some tumor tissues. The cytotoxicity test confirmed favorable safety and efficacy of the ADC. The mortality rate of cancer cells is about 85-90%. Moreover, the antibody nanoparticle-loaded drug showed distinguishing controlled release efficiency toward cancer cells induced by different levels of MMP-2 and pH. This enzyme-responsive FMSN-Dox-H2-AE01 offers a promising option for cancer therapy.